$OPTH

Optimi Health Corp.

Optimi Health manufactures pharmaceutical and nutraceutical products in Canada. Its controlled substance offerings include finished MDMA and psilocybin medications for authorized clinics, pharmacies, clinical trials and partners. The company also supplies psilocin, other psychedelic compounds and botanical functional mushrooms for health and wellness uses. Its activities include cultivating, processing and distributing mushroom biomass and extracts, as well as making mushroom supplements. Optimi Health sells through online channels, Amazon, distributors and brokers. It is based in Princeton, Canada.

1
1
0

No SEC Form 4 filings for $OPTH in the last 30 days.

See all $OPTH insider activity →
Med

Optimi Health Sets 2027 Clinical Agenda; Expects First Ibogaine Capsules Soon

Optimi Health (OPTH) outlined 2027 clinical trials for OPTI-101 (psilocybin for MDD) and OPTI-201 (MDMA for PTSD). Phase 2b and 3 trials planned, with U.S. IND applications expected. Ibogaine capsule production to begin soon. Proposed shares-for-debt settlement of US$240,000. OPTH stock is down 5.06% to $1.96.

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Curaleaf challenged Aurora's rejection of its $5-per-share takeover bid, accusing Aurora of obstructing the process. Decibel Cannabis clarified terms of a $5M share purchase offer from Ewing Morris. Optimi Health completed MDMA production for PTSD trials and commercial supply. Helus Pharma and Filament Health also reported advancements in psychedelic research.

Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity

Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) established Optimi Australia Pty Ltd, a subsidiary for distribution and business development in Australia, and appointed Adrian Jones as Director of Australian Operations. The subsidiary will handle sales and distribution of Optimi's psychedelic drug products, including psilocybin and MDMA capsules, to clinics and pharmacies under Australia’s Authorised Prescriber Scheme.

OPTH sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning OPTH (Optimi Health Corp.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.

Recent OPTH coverage spans financial news, technology and corporate actions.

What's driving OPTH

  • Clinical-program timeline and a related-party shares-for-debt settlement add near-term catalysts and financing overhang risk for OPTH.

    rttnews.com · Nov 18, 2026

  • The production milestone may lift sentiment for Optimi as it moves toward pivotal trial data.

    finance.yahoo.com · Oct 26, 2026

  • The new subsidiary could increase sales of psilocybin and MDMA products in Australia, potentially boosting revenue.

    recorder.ca · Oct 26, 2026

  • Optimi Health Corp. (OPTI) has produced a GMP batch of MDMA for use in a proposed Canadian Phase 3 PTSD trial, an Israeli trial, and Australian commercial exports. The company aims to supply these markets by the end of 2026, marking a shift towards commercial and late-stage clinical supply.

    tradingview.com · Oct 20, 2026

  • Potential upside if Phase 3 data are positive, supporting future regulatory filing and market expansion.

    rttnews.com · Sep 16, 2026

AlphAI scores every news story that mentions OPTH with an AI model for sentiment and relevance, and aggregates insider trades from Optimi Health Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $OPTH

Score

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Curaleaf challenged Aurora's rejection of its $5-per-share takeover bid, accusing Aurora of obstructing the process. Decibel Cannabis clarified terms of a $5M share purchase offer from Ewing Morris. Optimi Health completed MDMA production for PTSD trials and commercial supply. Helus Pharma and Filament Health also reported advancements in psychedelic research.

Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity

Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) established Optimi Australia Pty Ltd, a subsidiary for distribution and business development in Australia, and appointed Adrian Jones as Director of Australian Operations. The subsidiary will handle sales and distribution of Optimi's psychedelic drug products, including psilocybin and MDMA capsules, to clinics and pharmacies under Australia’s Authorised Prescriber Scheme.

REG - Optima Health PLC - Holding(s) in Company

Optima Health PLC (GB00BRSCY602) disclosed a major holding notification. Octopus Investments Limited crossed a voting rights threshold on 15-Sep-2026, with details submitted to the London Stock Exchange on 16-Sep-2026. The filing includes voting rights and financial instrument details, as required by UK regulations.

Related tickers